Dave Lennon, former president of Novartis Gene Therapies
Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
